{"id":"NCT01893411","sponsor":"Merz Pharmaceuticals GmbH","briefTitle":"Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy","officialTitle":"Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06","primaryCompletion":"2015-08","completion":"2016-05","firstPosted":"2013-07-09","resultsPosted":"2017-05-12","lastUpdate":"2021-08-05"},"enrollment":311,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Lower Limb Spasticity Due to Cerebral Palsy"],"interventions":[{"type":"DRUG","name":"IncobotulinumtoxinA (16 Units per kg body weight)","otherNames":["Xeomin","NT 201","Botulinum toxin type A (150 kiloDalton), free from complexing proteins"]},{"type":"DRUG","name":"IncobotulinumtoxinA (12 Units per kg body weight)","otherNames":["Xeomin","NT 201","Botulinum toxin type A (150 kiloDalton), free from complexing proteins"]},{"type":"DRUG","name":"IncobotulinumtoxinA (4 Units per kg body weight)","otherNames":["Xeomin","NT 201","Botulinum toxin type A (150 kiloDalton), free from complexing proteins"]}],"arms":[{"label":"16 Units per kg body weight incobotulinumtoxinA (Xeomin)","type":"EXPERIMENTAL"},{"label":"12 Units per kg body weight incobotulinumtoxinA (Xeomin)","type":"EXPERIMENTAL"},{"label":"4 Units per kg body weight incobotulinumtoxinA (Xeomin)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the leg(s) are effective in treating children/adolescents (age 2-17 years) with increased muscle tension/uncontrollable muscle stiffness (spasticity) due to cerebral palsy.","primaryOutcome":{"measure":"Change From Baseline in the Ashworth Scale (AS) Score of Plantar Flexors of the Primary Body Side at Day 29 (Week 4) of the First Injection Cycle (1st IC)","timeFrame":"Baseline, Week 4","effectByArm":[{"arm":"High Dose: 16 U/kg Body Weight IncobotulinumtoxinA (Xeomin)","deltaMin":-0.7,"sd":0.061},{"arm":"Low Dose: 4U/kg Body Weight Incobotulinumtoxin A (Xeomin)","deltaMin":-0.66,"sd":0.084}],"pValues":[{"comp":"OG000 vs OG002","p":"= 0.65"},{"comp":"OG001 vs OG002","p":"= 0.741"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":53,"countries":["Austria","Czechia","Estonia","France","Germany","Israel","Poland","Romania","Russia","Slovakia","South Korea","Spain","Turkey (Türkiye)","Ukraine"]},"refs":{"pmids":["34092664","36136523"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":156},"commonTop":["Nasopharyngitis","Bronchitis","Cough"]}}